Saturday, September 23, 2023
ADVERTISEMENTspot_img

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023. Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m. ET.

A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

            

GlobeNewswire is one of the world’s largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.

GlobeNewswire
GlobeNewswire
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest Articles

error: